Skip to Main Content

A Phase 1 Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

Conditions

Phase I

Phase I

What is the purpose of this trial?

The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1948 and determine the recommended Phase 2 dose (RP2D) of ASP1948. This study will also evaluate the antitumor effect of ASP1948.

  • Trial with
    Astellas Pharma US, Inc.
  • Start Date
    10/30/2018
  • End Date
    03/27/2021
Trial Image

For more information about this study, contact:

Stephanie Rosini

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/07/2020
  • Study HIC
    #2000023045